The FDA has approved a new option for the long-term maintenance treatment of airflow obstruction in individuals with chronic obstructive pulmonary disease.
More than 30 million people in the United States have chronic obstructive pulmonary disease. A recent study presented at the CHEST 2017 Annual Meeting compared outcomes in men and women who had been...
More than 30 million people in the United States have chronic obstructive pulmonary disease. A recent study presented at the CHEST 2017 Annual Meeting compared outcomes in men and women who had been...
Recently, researchers conducted a study to examine whether the presence of rheumatoid arthritis affected the risk of developing chronic obstructive pulmonary disease or asthma, independent of lifestyle...
Recently, researchers conducted a study to examine whether the presence of rheumatoid arthritis affected the risk of developing chronic obstructive pulmonary disease or asthma, independent of lifestyle...
The US Food and Drug Administration recently approved the first single dose once-daily inhaler to be used as maintenance therapy for patients with chronic obstructive pulmonary disease.
In 2 recent studies, researchers examined the safety and efficacy of adding mepolizumab to triple therapy in patients with COPD and an eosinophil phenotype.
In 2 recent studies, researchers examined the safety and efficacy of adding mepolizumab to triple therapy in patients with COPD and an eosinophil phenotype.
